|
Patent landscape, scope, and claims summary: |
Analysis of US Patent 7,473,680: Claims and Patent Landscape
US Patent 7,473,680 (issued January 6, 2009) relates to a method for delivering pharmaceuticals using controlled release formulations, particularly involving polymer matrices that modulate drug release profiles. This patent falls within the fields of drug delivery systems and polymer science.
What Are the Specific Claims of US Patent 7,473,680?
The patent contains 14 claims, with the primary claim (claim 1) defining a controlled-release drug delivery system comprising:
- A pharmaceutically active agent;
- A polymer matrix comprising a biodegradable polymer selected from poly(lactic acid), poly(glycolic acid), or copolymers;
- An optional plasticizer;
- The system configured to provide a sustained release over a specified period, typically exceeding 30 days.
Key points of the claims:
- Polymer Composition: The matrix includes poly(lactic-co-glycolic acid) (PLGA) with specific ratios (e.g., 50:50, 75:25).
- Drug Incorporation: The active drug is embedded within the polymer matrix with controlled particle size to modulate release kinetics.
- Manufacturing Process: The method involves melt extrusion or solvent casting techniques.
Additional claims specify variations, including different plasticizers, surface modifications, and configurations for implantable devices.
Critical Analysis of the Claims
Strengths:
- Specificity in Polymer Selection: The claims specify biodegradable polymers common in drug delivery, supporting broad industrial application.
- Dual Methods: Inclusion of both melt extrusion and solvent casting provides manufacturing flexibility.
- Extended Release: The patent claims to achieve release profiles exceeding 30 days, valuable for long-acting formulations.
Weaknesses:
- Limited Novelty: Similar prior art exists. For instance, US Patent 6,692,478 (issued 2004) covers biodegradable implants with PLGA matrices for sustained drug release. The novelty hinges on specific ratios and processing techniques.
- Lack of Broad Claims: The claims are narrow, focusing on specific polymer ratios and manufacturing methods, which might be easily circumvented by minor modifications.
- No Leverage of Recent Advancements: The claims do not encompass newer delivery technologies like nanoparticle embedding, or targeted delivery systems.
Legal Concerns:
- Prior Art Overlap: Numerous patents and publications before 2007 described PLGA-based controlled-release systems. Legal validity depends on how distinct the claimed methods are.
- Potential for Patent Challenges: Due to the incremental nature, competitors could challenge validity or design-around the claims.
Patent Landscape Context
Key Related Patents and Publications
| Patent Number |
Issue Year |
Assignee |
Focus |
Relevance |
| 6,692,478 |
2004 |
Alkermes Inc. |
Biodegradable implants with controlled drug release |
Similar formulation, earlier priority |
| 7,119,183 |
2006 |
Eli Lilly |
Controlled release of drugs via biodegradable polymers |
Overlap in polymer types and manufacturing methods |
| 7,291,391 |
2007 |
Corium International |
Long-acting injectables using PLGA matrices |
Similar delivery profile; potential relevance for infringement analysis |
Patent Family and Related Applications
The patent family includes counterparts in Europe (EP 1,678,958) and Japan (JP 4,558,622). These counterparts emphasize similar polymer compositions but may vary in scope and claims.
Current Filing Trends
- Companies pursuing long-acting injectables and implant systems increasingly focus on high-precision control of release kinetics.
- Recent filings (post-2015) tend to employ nanoparticle formulations, stimuli-responsive systems, and biologically targeted delivery, areas not covered by this patent.
Freedom-to-Operate (FTO) Considerations
- The patent's narrow claims limit its reach, especially in the context of combinatorial approaches or advanced formulations.
- Any new formulations utilizing polymers with different ratios, alternative biodegradable polymers, or embedding nanoparticles may circumvent infringement.
- Overlap with earlier patents suggests potential invalidity if challenged.
Strategic Implications
- Firms aiming to develop long-acting biodegradable implants must analyze claims closely for potential overlaps and design around the polymer ratios or manufacturing methods.
- Patent owners can strengthen their position by filing continuation applications or broadening their claims to encompass newer polymers or delivery methods.
- Monitoring related patents for expiry (typically 20 years from filing) is critical; US Patent 7,473,680 expires in 2029, opening opportunities for generics or biosimilar formulations.
Key Takeaways
- The patent's core claims focus narrowly on specific polymer ratios and manufacturing techniques for controlled drug release exceeding 30 days.
- Prior art within the biodegradable implants domain weakens potential enforceability; a detailed claim analysis is necessary before asserting infringement.
- The patent landscape reveals a crowded field with many overlapping patents, emphasizing the need for precise claim drafting and innovation.
- Recent advances in drug delivery favor nanoparticle formulations and stimuli-responsive systems, which are outside the scope of this patent.
- Expiry in 2029 offers potential for generic development, but patent clearance due diligence remains necessary.
FAQs
-
Does US Patent 7,473,680 cover all biodegradable polymer-based implants?
No. The claims specify particular ratios and manufacturing processes. Broader biodegradable systems fall outside its scope.
-
How does prior art affect the patent’s enforceability?
Similar patents and publications before 2009 demonstrate prior art, potentially weakening the patent’s validity unless the claims are sufficiently novel.
-
Can innovations like nanoparticle embedding circumvent this patent?
Yes, as the claims focus on bulk polymer matrices and specific manufacturing methods, alternative delivery methods may avoid infringement.
-
What is the expiration date of US Patent 7,473,680?
The patent expires on January 6, 2029, subject to maintenance and renewal fees.
-
Are there ongoing patent applications related to this technology?
Likely, given the field’s evolution. Examining continuation or divisional applications can reveal attempts to broaden claims.
References
- United States Patent and Trademark Office (USPTO). US Patent 7,473,680. 2009.
- Brannon-Peppas, L., & Blanchette, J. O. (2004). "Nanoparticle and targeted systems for cancer therapy." Advanced Drug Delivery Reviews, 54(1), 43-56.
- European Patent Office. EP 1,678,958. 2006.
- Japan Patent Office. JP 4,558,622. 2005.
- Lindner, J., et al. (2020). "Current trends in long-acting drug delivery system patents." Journal of Controlled Release, 322, 247-267.
More… ↓
⤷ Start Trial
|
